Those with preserved EF seemed to get more protection against HF events/CV death than those with reduced or unknown EF.
With the study adding to a mix of conflicting trial results, it’s not yet time to update guidelines, Shyam Prabhakaran says.
It’s a known problem, but treatment hasn’t improved in 20 years. Experts say it’s time for protocolized systems of care, they ...
The procurement and perfusion method, areas that are rapidly evolving, will likely play a role in the success of DCD transplants.
Though recombinant factor VIIa didn’t improve outcomes overall, treating very early and in those with a spot sign on CT may help.
Neither stenting nor endarterectomy provided a boost versus medical therapy alone in patients with asymptomatic stenosis.
Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and ...
A bundle of protocols including patient education, skin prep, and glove changes reduced infections at a large US surgical ...
The mechanism remains unclear, but GLP-1 users had less MACE, CV death, and all-cause death driven by fewer amputations.
The agency says there have been 22 injuries and no deaths associated with this potentially high-risk device issue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results